| Outcome Measures: |
Primary: Baseline Adjusted Hemoglobin A1c Over Time, Comparison of the baseline-adjusted differences in HbA1c between the metformin and placebo groups during the trial. Hemoglobin A1c is a marker of glycemic control. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model)., Baseline, 3mo, 6mo, and 9 months | Secondary: Baseline Adjusted Changes in Lipid Profile Over Time, Comparison of the baseline-adjusted differences in total cholesterol/high density cholesterol index over time between the metformin and the placebo groups. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model)., Baseline, 3mo, 6mo, and 9 months|Baseline Adjusted Changes in Adiponectin/Leptin Ratio Over Time, Comparison of the baseline-adjusted differences in adiponectin/leptin ratio over time between the metformin and the placebo groups. The reported values represented mean adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model)., Baseline, 3mo, 6 mo, and 9 months|Number of Participants With Minor, Major, and Nocturnal Hypoglycemia, Comparison of the occurrence of hypoglycemic event requiring a third party assistance (major hypoglycemia) per subject during the study, and minor hypoglycemia (plasma glucose of \<60 mg/dL or no measurement), as well as nocturnal hypoglycemia (plasma glucose of ≤60 mg/dL between 11PM and 6AM)., 12 months
|
